MedTrace Logo

The Effect of Bevacizumab on the Trabeculectomy

NCT01122966 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-05-26

No results posted yet for this study

Summary

The investigators plan to evaluate the additive effect of intracameral and subconjunctival injections of bevacizumab in trabeculectomies with other antimetabolites.

Conditions

Interventions

DRUG

intraocular injections of bevacizumab

intracameral and subconjunctival injections

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Changwon Kee, M.D., Ph.D · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-03-31
Completion
2012-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01122966 on ClinicalTrials.gov